Replies to post #154472 on Biotech Values

[DewDiligence]

MRK’s Tredaptive failure will make the EMA demand more clinical data for all chronic-use drugs, opines John LaMattina:

http://www.forbes.com/sites/johnlamattina/2013/01/02/will-mercks-failure-with-tredaptive-impact-how-drugs-are-approved-in-europe/

I think he’s right.